专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004076635A3 THERAPEUTIC APPLICATIONS OF THROMBOMODULIN GENE VIA VIRAL AND NON-VIRAL VECTORS 审中-公开
标题翻译：通过病毒和非病毒载体的血栓素基因的治疗应用
公开(公告)号：WO2004076635A3
公开(公告)日：2005-09-09
申请号：PCT/US2004005453
申请日：2004-02-25
申请人： BIOVEC B V , SEHGAL LAKSHMAN R , WONG JONATHAN , SETH PREM
发明人： SEHGAL LAKSHMAN R , WONG JONATHAN , SETH PREM
IPC分类号： A61K38/00 , A61K48/00 , C07K14/745 , C12N20060101 , C12N15/86 , C12N15/861
CPC分类号： C07K14/7455 , A61K38/00 , C12N15/86 , C12N2710/10343 , C12N2800/30
摘要： The present invention relates to methods and compositions for treating thrombotic diseases using gene delivery technologies. In one embodiment, a therapeutically effective amount of a TM gene product is expressed in a TM-deficient mammal using a viral or non viral vector. In another embodiment, the vector-mediated in vivo TM gene expression is used for the treatment of atherosclerotic cardiovascular disease, pulmonary hypertension, acute inflammatory diseases, end-stage renal failure disease, or Alzheimer disease. In yet another embodiment, a vector carrying a TM inhibitory polynucleotide in which the vector is introduced into a mammal to reduce the TM activity or TM gene expression in vivo.
摘要翻译：本发明涉及使用基因递送技术治疗血栓形成疾病的方法和组合物。在一个实施方案中，使用病毒或非病毒载体在TM缺陷型哺乳动物中表达治疗有效量的TM基因产物。在另一个实施方案中，载体介导的体内TM基因表达用于治疗动脉粥样硬化心血管疾病，肺动脉高压，急性炎性疾病，终末期肾衰竭疾病或阿尔茨海默病。在另一个实施方案中，携带TM抑制性多核苷酸的载体将载体导入哺乳动物以降低体内TM活性或TM基因表达。

2. 发明申请

WO9625507A2 METHODS OF PREPARATION AND USE OF RECOMBINANT ADENOVIRAL VECTORS 审中-公开
标题翻译：制备和使用重组腺病毒载体的方法
公开(公告)号：WO9625507A2
公开(公告)日：1996-08-22
申请号：PCT/US9602336
申请日：1996-02-16
申请人： US HEALTH , SETH PREM K , COWAN KENNETH
发明人： SETH PREM K , COWAN KENNETH
IPC分类号： C07K14/47 , C07K14/82 , C12N15/12 , C12N15/861 , C12N15/86 , A61K48/00 , C12N15/55
CPC分类号： C12N15/86 , C07K14/4703 , C07K14/82 , C12N2710/10343
摘要： The present invention describes novel methods of constructing recombinant adenoviral vectors capable of expressing human cDNAs, such as wild-type p53, WAF1/Cip1/p21, p27/kip1, E. coli cytosine deaminase, wild-type p16, TAM 67 (a jun/fos dominant negative mutant) and B7-1 and B7-2. The invention further provides methods of inhibiting the proliferation of cells, inhibiting the cell cycle of proliferating cells, and methods for the eradication of cells, especially cancer and diseased cells, by infecting the cells with a recombinant adenovirus vector capable of expressing human cDNAs. Compositions and methods of the invention are suitable for treatment of a subject afflicted with a tumor wherein the cells of the tumor, for example, lack the wild-type p53 allele and/or possess a mutated p53 gene. The invention additionally provides a method for the use of adenoviral vectors in the treatment of cancer cells, such as lung cancer and breast cancer cells. The invention further provides methods for the use of adenoviral vectors in cancer gene therapy as a mechanism for purging bone marrow cells of contaminanting tumor cells, for eradicating cancer cells, and for preventing development of cancer cells and tumors.
摘要翻译：本发明描述了构建能够表达人cDNA的重组腺病毒载体的新方法，例如野生型p53，WAF1 / Cip1 / p21，p27 / kip1，大肠杆菌胞嘧啶脱氨酶，野生型p16，TAM 67 / fos显性阴性突变体）和B7-1和B7-2。本发明还提供了通过用能够表达人cDNA的重组腺病毒载体感染细胞来抑制细胞增殖，抑制增殖细胞的细胞周期的方法，以及根除细胞，特别是癌症和患病细胞的方法。本发明的组合物和方法适用于治疗患有肿瘤的受试者，其中肿瘤的细胞例如缺少野生型p53等位基因和/或具有突变的p53基因。本发明另外提供了一种使用腺病毒载体来治疗癌细胞如肺癌和乳腺癌细胞的方法。本发明进一步提供了在癌基因治疗中使用腺病毒载体作为清除污染性肿瘤细胞的骨髓细胞，用于根除癌细胞和预防癌细胞和肿瘤的发展的机制的方法。

3. 发明申请

WO2008067025A3 ONCOLYTIC ADENOVIRUSES AND USES THEREOF 审中-公开
公开(公告)号：WO2008067025A3
公开(公告)日：2008-06-05
申请号：PCT/US2007/080098
申请日：2007-10-01
申请人： EVANSTON NORTHWESTERN HEALTHCARE , SETH, Prem
发明人： SETH, Prem
IPC分类号： A01N63/00 , A01N65/00 , A61K48/00
摘要： The disclosed subject matter provides methods and materials relating to viral vectors, such as adenoviral vectors, that effectively target cancer cells and that express a protein that specifically binds to Transforming Growth Factor-β.

4. 发明申请

WO2008067025A2 ONCOLYTIC ADENOVIRUSES AND USES THEREOF 审中-公开
标题翻译：炎症性腺病毒及其用途
公开(公告)号：WO2008067025A2
公开(公告)日：2008-06-05
申请号：PCT/US2007080098
申请日：2007-10-01
申请人： EVANSTON NORTHWESTERN HEALTHCA , SETH PREM
发明人： SETH PREM
IPC分类号： A61K48/00 , C12N15/861
CPC分类号： A61K35/76 , A01K67/0271 , A01K2227/105 , A01K2267/0331 , A61K35/761 , A61K38/179 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/10321 , C12N2710/10322 , C12N2710/10332 , C12N2710/10343 , A61K2300/00
摘要： The disclosed subject matter provides methods and materials relating to viral vectors, such as adenoviral vectors, that effectively target cancer cells and that express a protein that specifically binds to Transforming Growth Factor-ß.
摘要翻译：所公开的主题提供了有效靶向癌细胞并表达与转化生长因子-β特异性结合的蛋白质的病毒载体如腺病毒载体相关的方法和材料。

5. 发明申请

WO2004076635A2 THERAPEUTIC APPLICATIONS OF THROMBOMODULIN GENE VIA VIRAL AND NON-VIRAL VECTORS 审中-公开
标题翻译：通过病毒和非病毒载体进行血管生成素基因的治疗应用
公开(公告)号：WO2004076635A2
公开(公告)日：2004-09-10
申请号：PCT/US2004/005453
申请日：2004-02-25
申请人： BIOVEC B.V. , SEHGAL, Lakshman, R. , WONG, Jonathan , SETH, Prem
发明人： SEHGAL, Lakshman, R. , WONG, Jonathan , SETH, Prem
IPC分类号： C12N
CPC分类号： C07K14/7455 , A61K38/00 , C12N15/86 , C12N2710/10343 , C12N2800/30
摘要： The present invention relates to methods and compositions for treating thrombotic diseases using gene delivery technologies. In one embodiment, a therapeutically effective amount of a TM gene product is expressed in a TM-deficient mammal using a viral or non viral vector. In another embodiment, the vector-mediated in vivo TM gene expression is used for the treatment of atherosclerotic cardiovascular disease, pulmonary hypertension, acute inflammatory diseases, end-stage renal failure disease, or Alzheimer disease. In yet another embodiment, a vector carrying a TM inhibitory polynucleotide in which the vector is introduced into a mammal to reduce the TM activity or TM gene expression in vivo
摘要翻译：本发明涉及使用基因递送技术治疗血栓形成疾病的方法和组合物。在一个实施方案中，使用病毒或非病毒载体在TM缺陷型哺乳动物中表达治疗有效量的TM基因产物。在另一个实施方案中，载体介导的体内TM基因表达用于治疗动脉粥样硬化性心血管疾病，肺动脉高压，急性炎性疾病，终末期肾衰竭疾病或阿尔茨海默病。在另一个实施方案中，携带TM抑制性多核苷酸的载体将载体导入哺乳动物以降低体内TM活性或TM基因表达

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式